Short answer
HPV testing and Pap testing are mainly cervical cancer screening tools. They are related to a sexually transmitted virus, but they are not the same as a general STI panel and do not check for HIV, syphilis, chlamydia, gonorrhea, herpes, hepatitis, or trichomoniasis. If you are asking about STI exposure, ask separately about the infections and body sites that need testing.
HPV test versus Pap test
| Test | What it checks | What it does not answer |
|---|---|---|
| HPV test | High-risk HPV types linked to cervical cancer. | It is not a general test for all HPV types, genital warts, partners, or non-cervical body sites. |
| Pap test | Cervical cell changes that may become cancer if not followed up. | It is not a test for most STIs and does not diagnose every cause of symptoms. |
| HPV/Pap cotest | Both high-risk HPV and cervical cell changes. | It still does not replace STI testing for HIV, syphilis, chlamydia, gonorrhea, hepatitis, herpes, or trichomoniasis. |
Why HPV testing is different from an STI panel
CDC's STI treatment guidance says HPV tests are available for detecting oncogenic HPV types in the context of cervical cancer screening and follow-up of abnormal cervical results. CDC also says these tests should not be used as a general STI test, for male partners of women with HPV, for women younger than 25, or for diagnosis of genital warts.
That distinction matters because people often hear "HPV is an STI" and expect an STI panel to answer every HPV question. HPV can spread through close skin-to-skin touching during sex, so genital touching or rubbing can raise HPV anxiety, but cervical HPV testing is built around cancer prevention and follow-up, not around proving when HPV was acquired or whether a partner has HPV.
Common screening schedules
| Age group | Common US screening approach | Important caveat |
|---|---|---|
| Younger than 21 | Routine cervical cancer screening is generally not recommended. | Symptoms, immune status, HIV, DES exposure, prior precancer, or other special situations can change care. |
| 21 to 29 | HRSA and USPSTF describe cervical cytology, usually called a Pap test, as the screening approach for average-risk people in this age range. | NCI notes ACS guidance differs, recommending HPV-based screening starting at 25; ask which guideline your clinician uses. |
| 30 to 65 | HRSA's January 2026 update designates high-risk HPV testing, collected by a patient or clinician, as preferred for average-risk women while retaining Pap testing as an option. | USPSTF's current final clinical summary still lists Pap, high-risk HPV testing, and cotesting options. Coverage for the new HRSA guideline begins for most plans in 2027. |
| Older than 65 | Some people can stop after adequate prior normal screening. | Prior abnormal results, cancer history, hysterectomy details, HIV, immune suppression, or DES exposure can change the plan. |
Self-collection and at-home questions
FDA approved some HPV tests to use self-collected vaginal specimens in a health care setting in 2024. HRSA's 2026 update includes a self-collection option for average-risk women ages 30 to 65, and NCI reported in 2025 that expert consensus guidance considers self-collected vaginal specimens acceptable for primary HPV screening of asymptomatic average-risk individuals. Clinician-collected cervical specimens remain preferred for people with prior abnormal screening, colposcopy, or treatment history. Availability still depends on the exact FDA-cleared test, collection device, lab workflow, and follow-up plan.
What an abnormal result may mean
An abnormal Pap result or positive HPV result usually does not mean you have cervical cancer. CDC and NCI both emphasize that abnormal cervical screening results often reflect HPV infection or cell changes that can be monitored or treated before cancer develops. The next step may be repeat testing, HPV genotyping, colposcopy, biopsy, or treatment, depending on the exact result and history.
Questions to ask
- Am I due for cervical cancer screening based on my age and prior results?
- Is this a Pap test, HPV test, or cotest?
- If HPV testing is offered, is it clinician-collected or self-collected, and is that option approved for this setting?
- What will happen if the result is HPV positive, abnormal, unclear, or unsatisfactory?
- Do I also need separate STI testing based on partners, symptoms, pregnancy, body sites, or exposure timing?
- Can I use a free or low-cost cervical cancer screening program if cost is a barrier?